Karolina Kauppi

The paper identifies eight drug candidates for repurposing to treat cognitive symptoms in schizophrenia, with sex-specific recommendations based on gene expression differences.

This study examines sex-specific effects of polygenic risk for schizophrenia on cognitive functioning across the lifespan in healthy individuals, finding male-specific associations.

This study evaluates whether a polygenic hazard score (PHS) can enhance the prediction of amyloid and tau deposition and progression to Alzheimer’s dementia when combined with biomarkers in nondemented individuals.

This paper develops and validates a polygenic hazard score to predict age-specific Alzheimer's disease risk using genetic data from multiple cohorts.